These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 32124093)
1. A Microfluidic Perfusion Platform for In Vitro Analysis of Drug Pharmacokinetic-Pharmacodynamic (PK-PD) Relationships. Guerrero YA; Desai D; Sullivan C; Kindt E; Spilker ME; Maurer TS; Solomon DE; Bartlett DW AAPS J; 2020 Mar; 22(2):53. PubMed ID: 32124093 [TBL] [Abstract][Full Text] [Related]
2. Generation and functional assessment of 3D multicellular spheroids in droplet based microfluidics platform. Sabhachandani P; Motwani V; Cohen N; Sarkar S; Torchilin V; Konry T Lab Chip; 2016 Feb; 16(3):497-505. PubMed ID: 26686985 [TBL] [Abstract][Full Text] [Related]
3. Microfluidic-enabled self-organized tumor model for in vitro cytotoxicity assessment of doxorubicin. Yang Y; Liu S; Chen C; Huang H; Tao L; Qian Z; Li W Biomed Microdevices; 2020 Sep; 22(4):70. PubMed ID: 32960346 [TBL] [Abstract][Full Text] [Related]
4. A Novel Integrated Pharmacokinetic-Pharmacodynamic Model to Evaluate Combination Therapy and Determine Choi YH; Zhang C; Liu Z; Tu MJ; Yu AX; Yu AM J Pharmacol Exp Ther; 2021 Jun; 377(3):305-315. PubMed ID: 33712506 [TBL] [Abstract][Full Text] [Related]
5. A programmable microfluidic cell array for combinatorial drug screening. Kim J; Taylor D; Agrawal N; Wang H; Kim H; Han A; Rege K; Jayaraman A Lab Chip; 2012 Apr; 12(10):1813-22. PubMed ID: 22456798 [TBL] [Abstract][Full Text] [Related]
6. A versatile dilution-treatment-detection microfluidic chip platform for rapid In vitro lung cancer drug combination sensitivity evaluation. Zhang C; Tian K; Meng Z; Zhang J; Lu Y; Tan L; Zhang M; Xu D Talanta; 2024 Sep; 277():126298. PubMed ID: 38823330 [TBL] [Abstract][Full Text] [Related]
7. Viability analysis and apoptosis induction of breast cancer cells in a microfluidic device: effect of cytostatic drugs. Komen J; Wolbers F; Franke HR; Andersson H; Vermes I; van den Berg A Biomed Microdevices; 2008 Oct; 10(5):727-37. PubMed ID: 18523888 [TBL] [Abstract][Full Text] [Related]
8. Modeling Pharmacokinetic Profiles for Assessment of Anti-Cancer Drug on a Microfluidic System. Guo Y; Deng P; Chen W; Li Z Micromachines (Basel); 2020 May; 11(6):. PubMed ID: 32486116 [TBL] [Abstract][Full Text] [Related]
9. Multi-functional scaling methodology for translational pharmacokinetic and pharmacodynamic applications using integrated microphysiological systems (MPS). Maass C; Stokes CL; Griffith LG; Cirit M Integr Biol (Camb); 2017 Apr; 9(4):290-302. PubMed ID: 28267162 [TBL] [Abstract][Full Text] [Related]
10. A Diffusion-Based and Dynamic 3D-Printed Device That Enables Parallel in Vitro Pharmacokinetic Profiling of Molecules. Lockwood SY; Meisel JE; Monsma FJ; Spence DM Anal Chem; 2016 Feb; 88(3):1864-70. PubMed ID: 26727249 [TBL] [Abstract][Full Text] [Related]
11. A microfluidic platform for functional testing of cancer drugs on intact tumor slices. Rodriguez AD; Horowitz LF; Castro K; Kenerson H; Bhattacharjee N; Gandhe G; Raman A; Monnat RJ; Yeung R; Rostomily RC; Folch A Lab Chip; 2020 May; 20(9):1658-1675. PubMed ID: 32270149 [TBL] [Abstract][Full Text] [Related]
12. On the potential of in vitro organ-chip models to define temporal pharmacokinetic-pharmacodynamic relationships. McAleer CW; Pointon A; Long CJ; Brighton RL; Wilkin BD; Bridges LR; Narasimhan Sriram N; Fabre K; McDougall R; Muse VP; Mettetal JT; Srivastava A; Williams D; Schnepper MT; Roles JL; Shuler ML; Hickman JJ; Ewart L Sci Rep; 2019 Jul; 9(1):9619. PubMed ID: 31270362 [TBL] [Abstract][Full Text] [Related]
13. A cell culture system to model pharmacokinetics using adjustable-volume perfused mixing chambers. Erickson P; Jetley G; Amin P; Mejevdiwala A; Patel A; Cheng K; Parekkadan B Toxicol In Vitro; 2023 Sep; 91():105623. PubMed ID: 37236431 [TBL] [Abstract][Full Text] [Related]
15. Novel Chip for Applying Mechanical Forces on Human Skin Models Under Dynamic Culture Conditions. Kaiser K; Sørensen JA; Brewer JR Tissue Eng Part C Methods; 2024 Feb; 30(2):85-91. PubMed ID: 37950718 [TBL] [Abstract][Full Text] [Related]
16. A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI). Shinozaki K; Yamada T; Nasu J; Matsumoto T; Yuasa Y; Shiraishi T; Nagano H; Moriyama I; Fujiwara T; Miguchi M; Yoshida R; Nozaka K; Tanioka H; Nagasaka T; Kurisu Y; Kobayashi M; Tsuchihashi K; Inukai M; Kikuchi T; Nishina T Int J Clin Oncol; 2021 Feb; 26(2):399-408. PubMed ID: 33097971 [TBL] [Abstract][Full Text] [Related]
17. A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies. Federico SM; Pappo AS; Sahr N; Sykes A; Campagne O; Stewart CF; Clay MR; Bahrami A; McCarville MB; Kaste SC; Santana VM; Helmig S; Gartrell J; Shelat A; Brennan RC; Hawkins D; Godwin K; Bishop MW; Furman WL; Stewart E Eur J Cancer; 2020 Sep; 137():204-213. PubMed ID: 32795876 [TBL] [Abstract][Full Text] [Related]
18. Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan. Kashiwa M; Matsushita R Clin Ther; 2020 Jul; 42(7):1361-1375. PubMed ID: 32616433 [TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant FOLFIRINOX followed by Chemoradiotherapy for Middle and Lower Rectal Cancer. Sakr A; Elsherbiny M; Abdel Moneim R; Shaaban S; Aldaly M Asian Pac J Cancer Prev; 2020 Jun; 21(6):1717-1723. PubMed ID: 32592369 [TBL] [Abstract][Full Text] [Related]